Empagliflozin was tested in the EMPA-REG trial, which was specific to patients with atherosclerotic vascular disease. CANVAS, which evaluated canagliflozin, and the DECLARE-TIMI 58 trial, which evaluated dapagliflozin, included patients with risk factors https://www.healio.com/cardiology/diabetes/news/online/%7Be27057cf-4713-46dd-bfdf-13a1aa58c941%7D/qa-a-closer-look-at-class-effects-of-sglt2-inhibitors-on-cv-outcomes-in-diabetes

Eli Lilly & Co. is expanding its collaboration with Evidation Health into a multiyear project aimed at developing digital biomarkers for disease, derived from smartphones, wearable sensors and even voice data. Lilly’s global scientists and researcher https://www.fiercebiotech.com/medtech/eli-lilly-and-evidation-expand-digital-biomarker-collaboration-to-data-from-smartphones-and

The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S. The research https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-partner-with-duke-clinical-research-institute-to-advance-multidisciplinary-care-for-people-with-type-2-diabetes-and-cardiovascular-disease-300764687.html

Mylan N.V. today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and found all claims of Sanofi’s Lantus (insulin glargine 100 Units/mL) formulation patents unp https://www.prnewswire.com/news-releases/sanofis-formulation-patents-on-multibillion-dollar-lantus-are-invalidated-by-us-patent-and-trademark-office-via-ipr-announces-mylan-300764745.html

Guidance documents released by the FDA on Tuesday outlining a new pathway for biologic products will help promote competition and lower prices for drugs with historically high list prices, including insulin and human growth hormone, according to a statem https://www.healio.com/endocrinology/diabetes/news/online/%7B4815c7c8-78cf-4710-a66f-46230dfc0c6c%7D/new-biosimilar-pathway-for-insulin-aims-to-promote-lower-prices-competition

Drug firm AstraZeneca Pharma India Friday said it has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India. Under the agreement, Abbott will promote and distribute Dapagliflozin under t https://health.economictimes.indiatimes.com/news/pharma/astrazeneca-pharma-inks-distribution-pact-with-abbott-for-diabetes-drug/66982577